Abstracts tagged "hyperuricemia and renal disease"

Abstract Number: 333 • 2019 ACR/ARP Annual Meeting
Assessing the Relationship Between Gout and Return to Hemodialysis Among U.S. Renal Transplant Patients
Justin Li¹, David Yin ¹, Zheng Wang ¹, Mark Brigham ¹, Brian LaMoreaux ², Jeffrey Kent ², Megan Francis-Sedlak ², Richard Johnson ³, Nandini Hadker ¹ and Gavin Miyasato ¹, ¹Trinity Partners, Waltham, MA, ²Horizon Therapeutics plc, Lake Forest, IL, ³University of Colorado Denver, Aurora, CO
Background/Purpose: Although gout has been shown to be associated with poor renal outcomes among chronic kidney disease populations, this relationship is not well understood among…
Abstract Number: 912 • 2016 ACR/ARHP Annual Meeting
Urate Lowering Therapy in Moderate to Severe Chronic Kidney Disease
Gerald D. Levy^1,2, Craig Cheetham³, Nazia Rashid⁴ and Jiaxiao Shi³, ¹Internal Medicine/Rheumatology, Southern California Kaiser Permanente, Downey, CA, ²Rheumatology, Kaiser Permanente Southern California, Downey, CA, ³Research and Evaluation, Southern California Medical Group, Pasadena, CA, ⁴Pharmacy Analytic Services, Kaiser Permanente, Downey, CA
Urate Lowering Therapy in Moderate to Severe Chronic Kidney Disease Levy G, Cheetham C, Shi J, Rashid N Background/Purpose: To determine if urate lowering…
Abstract Number: 2349 • 2015 ACR/ARHP Annual Meeting
The Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients with Severe Renal Impairment
Ji Seon Oh and Seungwon Choi, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea
Background/Purpose: Febuxostat has shown to be effective and safe in the treatment of hyperuricemia in patients with mild-to-moderate renal impairment without dose adjustment. However, there…
Abstract Number: 232 • 2015 ACR/ARHP Annual Meeting
Hyperuricemia, Urate Lowering Therapy and Kidney Function: A Systemic Review and Meta-Analysis
Gaurav Sharma¹, Abhishek Dubey¹ and Jasvinder A. Singh², ¹Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To determine whether hyperuricemia is associated with deterioration of kidney function and to examine whether urate-lowering therapies (ULTs) can improve or maintain kidney function.…
Abstract Number: 153 • 2012 ACR/ARHP Annual Meeting
Prevention of Recurrent Calcium Stones in Subjects with Hyperuricosuria: A Randomized Controlled Trial of Febuxostat Vs Allopurinol
David S. Goldfarb¹, Patricia A. MacDonald², Lhanoo Gunawardhana³, Solomon Chefo³ and Lachy McLean⁴, ¹New York Universtiy Langone Medical Center, New York, NY, ²Takeda Pharmaceuticals USA, Inc., Deerfield, IL, ³Takeda Global Research & Development Center, Inc., Deerfield, IL, ⁴Takeda Global Research & Development Center, Inc, Deerfield, IL
Background/Purpose: About one-third of patients with recurrent calcium oxalate (CaOx) stones have hyperuricosuria as a urinary risk factor. Febuxostat (FEB), a newer xanthine oxidase inhibitor…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.